

Lomeguatrib, a Potent Inhibitor of O^6 -Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Malcolm Ranson,¹ Mark R. Middleton,¹ John Bridgewater,⁴ Siow Ming Lee,⁴ Martin Dawson,² Debra Jowle,¹ Gavin Halbert,⁶ Sue Waller,⁵ Helen McGrath,⁵ Lindsey Gumbrell,⁵ R. Stanley McElhinney,⁷ Dorothy Donnelly,⁷ T. Brian H. McMurry,⁷ and Geoffrey P. Margison³

Abstract Purpose: A major mechanism of resistance to temozolomide involves the DNA repair protein O^6 -alkylguanine-DNA-alkyltransferase (ATase). The main aims of this phase I trial were to determine an ATase-depleting dose (ADD) of lomeguatrib, a potent pseudosubstrate inhibitor, and to define a suitable dose of temozolomide to be used in combination with lomeguatrib in patients with advanced cancer.

Experimental Design: Lomeguatrib was administered at dose levels of 10 to 40 mg/m² days 1 to 5, as a single agent, and also in combination with temozolomide. Once the ADD of lomeguatrib was identified, the dose of temozolomide in combination was increased, in successive patient cohorts, from 50 to 175 mg/m² on days 1 to 5 of a 28-day cycle to define the maximal tolerated dose and dose-limiting toxicity of the combination.

Results: Thirty-eight patients with advanced solid tumors were enrolled. More than 95% ATase depletion within 4 hours of the first dose was achieved in peripheral blood mononuclear cells at lomeguatrib doses of ≥ 10 mg/m²/d i.v. or ≥ 20 mg/m²/d orally, and tumor biopsies showed $\geq 92\%$ ATase depletion. At the ADD of lomeguatrib i.v., the maximal tolerated dose of temozolomide in combination was 150 mg/m² days 1 to 5. The dose limiting toxicity of the combination of lomeguatrib and temozolomide was myelosuppression. The toxicity of lomeguatrib alone was minimal. In 23 patients with measurable disease, one complete response was seen and 12 patients had stable disease for at least 3 months.

Conclusion: This first administration of lomeguatrib to man successfully established an oral ADD of lomeguatrib and identified a combination regimen with temozolomide suitable for future clinical evaluation.

Chloroethylnitrosoureas such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and methylating agents such as dacarbazine and temozolomide are cytotoxic through their ability to alkylate DNA, principally at the O^6 position in guanine (1–3).

Resistance to these agents can be conferred by the repair protein O^6 -alkylguanine-DNA alkyltransferase (ATase), which removes the alkyl group in a stoichiometric auto-inactivating reaction (1, 4, 5). Tumor cells frequently express high levels of ATase (6, 7).

ATase-mediated resistance to O^6 -alkylating agents can be overcome by depleting cellular levels before drug administration (8, 9). Early approaches used methylating agents to deplete ATase before treatment with chloroethylating drugs but met with little success. The common toxicities of the drugs used severely limited the doses of chloroethylating agent that could be given (10–13).

ATase can also be inactivated by low molecular weight pseudosubstrates (14–17). One such pseudosubstrate, O^6 -benzylguanine, has undergone phase I and II trials in combination with BCNU and further trials are in progress (18–22). In combination with ATase inhibitory doses of O^6 -benzylguanine, only 20% to 25% of the single agent BCNU dose is deliverable (18, 20, 22) and this may limit the therapeutic effect of the O^6 -benzylguanine/BCNU combination.

Lomeguatrib [6-(4-bromo-2-thienyl) methoxy]purin-2-amine] is more potent than O^6 -benzylguanine and has shown promising activity in sensitizing a variety of human tumor

Authors' Affiliations: ¹Department of Medical Oncology, University of Manchester; ²Cancer Research UK Clinical and Experimental Pharmacology Group and ³Cancer Research UK Carcinogenesis Group, Paterson Institute for Cancer Research, Manchester, United Kingdom; ⁴Department of Oncology, Royal Free and University College Medical School, University College; ⁵Cancer Research UK Drug Development Office, London, United Kingdom; ⁶Cancer Research UK Formulation Unit, Strathclyde University, Glasgow, United Kingdom; and ⁷Chemistry Department, Trinity College, Dublin, Ireland

Received 10/6/05; revised 11/18/05; accepted 12/15/05.

Grant support: Cancer Research UK and Christie Hospital Endowment Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: M. Ranson and M.R. Middleton are co-first authors.

Requests for reprints: Mark R. Middleton, Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ, United Kingdom. Phone: 44-1865-226185; Fax: 44-1865-226179; E-mail: mark.middleton@cancer.org.uk.

©2006 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-05-2198

xenografts to the growth inhibitory effects of temozolomide and other O^6 -alkylating agents (16, 23). Tumor growth delay was observed in A375 (melanoma), HT144 (melanoma), MCF-7 (breast), and DU-145 (prostate) xenograft models (16, 23).⁸ The efficacy of lomeguatrib and temozolomide given daily for 5 days was greater than that achievable at the maximal tolerated dose (MTD) of temozolomide alone, even with adjustment of scheduling to maximize antitumor efficacy (16). The additional antitumor activity was achievable at the expense of only limited additional toxicity and without major dose reduction of the O^6 -alkylating agent. Preclinical toxicologic assessment of lomeguatrib and temozolomide showed no additional toxicity to the dose limiting myelosuppression seen with temozolomide alone (Cancer Research UK data on file). Lomeguatrib was also effective in ATase inactivation and tumor growth inhibition after oral administration (Cancer Research UK data on file) thereby facilitating oral use and variations in dose schedule.

The objectives of this phase I trial were as follows:

- To determine the dose of lomeguatrib administered i.v. that inactivates $\geq 95\%$ of ATase in peripheral blood mononuclear cells (PBMC) and tumor at 4 hours [i.e. the ATase-depleting dose (ADD)].
- To determine the toxicity profile of lomeguatrib after i.v. and oral administration.
- To determine the toxicity profile, dose limiting toxicity (DLT), and MTD of oral temozolomide in patients receiving lomeguatrib at the ADD over a 5-day schedule.
- To determine the pharmacokinetic profile of lomeguatrib.
- To identify a suitable regimen of lomeguatrib and temozolomide for phase II evaluation.

This phase I study was the first involving the administration of lomeguatrib to humans.

Patients and Methods

Inclusion and exclusion criteria. Patients with histologically proven cancer refractory to conventional treatment or for which no suitable conventional therapy existed were eligible. Patients were required to be ≥ 18 years of age with a Karnofsky performance status of ≥ 70 and an expected survival of ≥ 12 weeks. They needed adequate hematologic and biochemical function with hemoglobin ≥ 10.0 g/dL, WBC $\geq 3.0 \times 10^9$ /L, neutrophil count $\geq 1.5 \times 10^9$ /L, platelets $\geq 100 \times 10^9$ /L, serum creatinine ≤ 130 μ mol/L, serum bilirubin ≤ 20 μ mol/L, and serum aspartate aminotransferase or alanine aminotransferase $\leq 2 \times$ upper limit of normal.

Patients were excluded if they had major thoracic or abdominal surgery, chemotherapeutic agents, or radiotherapy in the preceding 4 weeks; had mitomycin C or nitrosoureas within previous 6 weeks; had persistent toxic manifestations of previous treatments (except alopecia); had active infection or significant nonmalignant intercurrent illness; were pregnant or lactating; with known central nervous system metastases; with history of seizures; or were receiving concurrent antacid medication. A negative serum pregnancy test was required in women with child-bearing potential and all patients were required to use medically approved contraceptive precautions during the study and for 4 weeks afterwards.

The study was conducted under the auspices of Cancer Research UK in accordance with the principles of the International Conference on Harmonisation of Good Clinical Practice guidelines and the Declara-

tion of Helsinki. The trial was approved by the Cancer Research UK Independent Ethics Committee and the Local Research Ethics Committee of each trial center. All patients gave written informed consent.

Treatment. The i.v. formulation of lomeguatrib was supplied by Cancer Research UK Formulation Unit as a freeze-dried powder in glass vials containing 100 mg lomeguatrib and polyvinylpyrrolidone as a bulking agent. The vials were stored at 4°C. Lomeguatrib was reconstituted using 10 mL Pharmsolve (*N*-methylpyrrolidone) before diluting with 0.9% NaCl to a final concentration of 2 mg/mL. Intravenous administration was over 30 minutes via a peripheral venous cannula and commenced within 1 hour of reconstitution. The oral formulation of lomeguatrib was supplied by Cancer Research UK Formulation Unit as 10 mg enteric-coated capsules and stored at 4°C. Temozolomide was supplied by Schering Plough (Kenilworth, NJ) in capsule strengths of 5, 20, 100, and 250 mg. Temozolomide was stored at 2°C to 30°C in accordance with the instructions of the manufacturer. When administered in combination with temozolomide, lomeguatrib was administered 2 hours before temozolomide, and for oral dosing, the patient fasted for 1 hour pre- and post-dosing.

The starting dose of lomeguatrib both i.v. and orally was 10 mg/m² on days 1 to 5. The starting dose level of 10 mg/m² was approximately a third of the lomeguatrib dose in the mouse and rat that produced $\geq 95\%$ inactivation of ATase in liver at 4 hours following a single dose. The human ADD was predefined as the dose of lomeguatrib that produced $\geq 95\%$ ATase depletion in PBMC at 4 hours in all patients at that dose level.

To assess the toxicity and ATase-depleting effects of lomeguatrib alone and to establish the bioavailability of oral lomeguatrib, patients initially received lomeguatrib alone. Lomeguatrib was administered on days 1 to 5 and days 15 to 19. The initial route of administration could be oral or i.v. with the alternative route of administration being used on days 15 to 19. Because the oral formulation of lomeguatrib was not available at the start of the trial, patients 1 to 6 received lomeguatrib only via the i.v. route before entering the combination phase. At day 28, patients received lomeguatrib i.v. and temozolomide on days 1 to 5 of a 4-weekly cycle for up to six cycles.

A minimum of three patients was treated at each dose level and any patient withdrawn before day 21 of the combination phase was replaced. The first patient at each dose level was observed for 3 weeks before the enrollment of subsequent patients at that dose level. All three patients at a dose level were required to complete one 28-day treatment cycle with the combination of lomeguatrib and temozolomide before a decision to dose escalate temozolomide could be made. If one of three patients at a dose level developed DLT, up to three additional patients were treated at that dose level. If one of the three additional patients developed a DLT, dose escalation ceased and a total of six patients were treated at the preceding dose level. This lower dose level was defined as the MTD unless ≥ 2 of 6 patients developed DLT. If a patient developed DLT but was felt to be benefiting from treatment, the patient was permitted to continue at the discretion of the investigator following temozolomide dose reduction.

Dose escalations. The initial study design comprised two dose escalations. First, the dose of lomeguatrib was escalated to define the ADD of lomeguatrib. During this phase, the temozolomide dose was fixed at 50 mg/m² days 1 to 5. Once an ADD of lomeguatrib had been identified in PBMC, six consecutive patients who had given consent for paired tumor biopsies were entered. Tumor biopsies pretreatment and at 4 hours post-dosing on day 1 were obtained to verify adequate ATase depletion.

Once an ADD had been defined, the lomeguatrib dose was fixed at the ADD. The dose of temozolomide was escalated by 25 mg/m²/d increments in successive patient cohorts to define the MTD and DLT of temozolomide when administered with the ADD of lomeguatrib (Table 1).

On the basis of results obtained during the course of the trial, two further patient cohorts were then studied. The purpose of these cohorts was to evaluate lomeguatrib given orally in combination with

⁸ M.R. Middleton, unpublished data.

Table 1. Dose levels of lomeguatrib and temozolomide

Dose level	Lomeguatrib (mg/m ² /d) days 1-5	Temozolomide (mg/m ² /d) days 1-5	No. patients assigned dose level	No. patients receiving combination	Total no. cycles
1	10	50	6	6	12
2	10	75	3	3	8
3	10	100	6	4	8
4	10	125	4	3	12
5	10	150	7	7	26
6	10	175	3*	2	2
7	20	125	6	6	15 [†]
8	40	125	3	3	9 [‡]

* Patient #29 was originally assigned dose level 6 but, because patients #27 and #28 had DLT, was treated at dose level 5.

† Escalated to 150 mg/m² in a total of four cycles.

‡ Three cycles at reduced temozolomide dose after toxicity.

temozolomide as this was the favored formulation for future studies. Variability in ATase depletion with oral lomeguatrib made it desirable to test the MTD of temozolomide at greater than the ADD of i.v. lomeguatrib so as to better inform the selection of a combination for phase II studies (dose levels 7 and 8, Table 1).

Toxicity and response evaluation. The pretreatment evaluation included a complete medical history and physical examination, full blood count, biochemical profile, urinalysis, and electrocardiogram. Females with child-bearing potential underwent a pregnancy test. Baseline chest radiographs and appropriate radiology to evaluate tumor sites were done. Safety and toxicity were evaluated at least weekly during the study period and toxicities were graded according to the National Cancer Institute Common Toxicity Criteria Version 2 (24).

DLT was defined as any of the following events: (a) grade 4 neutropenia lasting >5 days or if associated with infection/fever; (b) grade 4 thrombocytopenia for >5 days; (c) grade 3 or 4 nonhematologic toxicity (excluding grade 3 nausea and vomiting in patients who had not received optimal treatment with antiemetics); and (d) drug-related death. The MTD was defined as the dose level of temozolomide in combination with the ADD of lomeguatrib below that at which $\geq 30\%$ of the patient population experienced DLT due to the drug combination. Patients were to be followed up until 4 weeks after the last drug administration. Tumor response was assessed using WHO response criteria (25) at baseline, after every two cycles, and after withdrawal.

Treatment delay, dose modification, and treatment withdrawal. A treatment delay of up to 2 weeks was allowed for resolution of drug-related toxicity. Dose modification of temozolomide by one or two dose levels was permitted in the event of DLT in the preceding cycle. Patients could be withdrawn from the study for progressive disease, unacceptable toxicity, serious violation of the study drug protocol, or withdrawal of consent.

Pharmacodynamics. Samples for PBMC ATase activity were obtained before treatment and at 0.5, 0.75, 1, 2, 4, 6, and 12 hours on days 1 and 5, and at days 8, 11, 15, and 22 following lomeguatrib alone and following lomeguatrib and temozolomide. Five to ten milliliters of venous blood were collected into tubes containing 100 μ L of 0.5 mol/L EDTA and stored on ice for a maximum of 4 hours before isolation of PBMC and analysis of ATase (26). Tumor biopsies were obtained by excision or core biopsy before and 4 hours after completion of the first dose of lomeguatrib. The biopsies were snap frozen on dry ice and stored at -80°C before determination of ATase activity (26).

Pharmacokinetics. Five-milliliter venous blood samples were drawn pre-dose and at 0.5, 0.75, 1, 2, 4, 6, and 12 hours post-dose for assay of lomeguatrib plasma levels on days 1 and 5 of administration. Samples were drawn into lithium heparin tubes and centrifuged immediately (if unable to centrifuge immediately, samples were placed on ice for <2

hours). Plasma was transferred to labeled tubes and frozen on dry ice before storage at -70°C . Lomeguatrib concentrations were determined by liquid chromatography-tandem mass spectrometry. Aliquots of plasma were added to deuterated lomeguatrib to give a concentration of 100 pg/ μ L as the internal standard. Patient plasma samples and standards were extracted by solid-phase extraction and analyzed within 30 minutes. Quality control sample and standard curve sample were each analyzed in triplicate.

Data analysis. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria Version 2 (24). Tumor response was defined according to WHO criteria (25). Area under the concentration time curve (AUC) was calculated using the trapezoidal rule for the sum of AUC to the last measured time point. Each patient's data were analyzed by nonlinear least squares regression to determine individual pharmacokinetic variables. ATase depletion data were summarized by dose level.

Results

Patient and tumor characteristics. Thirty-eight patients were enrolled and their baseline characteristics are shown in Table 2. All patients were evaluable for toxicity following lomeguatrib alone and 34 patients received lomeguatrib plus temozolomide and were evaluable for toxicity of the combination. Twenty-three patients had measurable disease and were evaluable for tumor response. The dose levels of lomeguatrib and temozolomide studied are shown in Table 1.

Determination of the ADD of lomeguatrib. Of the 38 patients entered, 37 patients were assessable for ATase depletion in PBMC following i.v. lomeguatrib administration (10 mg/m², 28 patients; 20 mg/m², 6 patients; 40 mg/m², 3 patients). PBMC samples were spoiled in one patient. Twenty-six patients were assessable for ATase depletion in PBMC following oral lomeguatrib (10 mg/m², 18 patients; 20 mg/m², 5 patients; 40 mg/m², 3 patients). In the cases not assessable, six patients were enrolled before oral lomeguatrib was available, three patients had undetectable ATase in the pretreatment sample, two samples were spoiled, and one patient was withdrawn before oral lomeguatrib dosing.

The determination of ADD was based on the percentage depletion observed 4 hours after the first dose of lomeguatrib. Depletion was rapid after i.v. dosing, with ATase usually undetectable at 30 minutes (end of lomeguatrib infusion),

Table 2. Patient and tumor characteristics

No. patients	38
Male/female	18/20
Median age, y (range)	60 (18-74)
Performance status (Karnofsky)	
90	30
80	5
70	3
Primary tumor site	
Melanoma	11
Colorectal	9
Non – small cell lung	4
Renal	3
1° peritoneal carcinoma	2
Ovary	2
Other	7*
Prior treatment	
Surgery	37
Radiotherapy	12
Hormonal/biological	11
Chemotherapy	32
Prior chemotherapy	
Median no. prior regimens (range)	2 (1-6)

*One each for breast, mesothelioma, esophagus, soft tissue sarcoma, neuroectodermal, stomach, and thymus.

whereas after oral dosing, depletion occurred after a lag phase of 60 to 120 minutes. Complete depletion of ATase was observed in 26 of 28 assessable patients receiving 10 mg/m² lomeguatrib i.v., and in the remaining 2 patients, ATase depletion was 97.3% and 98.2%. Thus, 10 mg/m² i.v. was identified as the ADD for PBMC. Oral lomeguatrib at 10 mg/m² (in effect 20 mg daily dose due to 10 mg capsule size) resulted in 100% depletion in 10 of 18 patients at 4 hours post day 1 dosing. In the remaining 8 patients, depletion at 4 hours post day 1 dose ranged from 75.8 to 96.2%. Additional ATase depletion was seen at time points later than 4 hours in all except one patient with complete/maximal depletion usually seen at 6 hours. Intravenous or oral lomeguatrib at doses of 20 mg/m² (five patients) and 40 mg/m² (three patients) produced 100% ATase depletion within 4 hours in all patients. Partial

recovery of ATase levels in PBMCs was observed by day 8 (3 days after the last dose of lomeguatrib) and levels continued to increase through days 11 to 15 (Table 3). The pattern of recovery was similar at all three dose levels and via both routes of administration.

Tumor ATase depletion following lomeguatrib. Tumor biopsies were obtained immediately before treatment and at 4 hours after 10 mg/m² lomeguatrib i.v. on day 1 in a total of 12 patients. In two cases, necrotic material was obtained and in one patient the pretreatment tumor sample had no detectable ATase. In six of the nine assessable patients, 100% ATase depletion was observed, and in the remaining three cases, depletion was 92.3%, 96.1%, and 96.6%.

ATase depletion in PBMC in patients receiving lomeguatrib and temozolomide. PBMC ATase depletion data were obtained in 33 patients treated with lomeguatrib and temozolomide. Four patients were withdrawn before combination therapy and one patient's samples were unsuitable for analysis. In all but one case, ATase depletion was 100% at 4 hours and in the remaining patient, depletion was 96.3% and complete by the end of dosing. The pattern of ATase recovery was similar to that seen for lomeguatrib alone although in some patients the recovery was slightly slower.

Pharmacokinetics of lomeguatrib. Table 4 summarizes the pharmacokinetics of lomeguatrib at each of the three dose levels studied. Following i.v. administration, plasma concentrations of lomeguatrib decreased rapidly and were biphasic, with an initial half-life $T_{1/2\alpha}$ of ~30 minutes and a $T_{1/2\beta}$ of ~3 hours. Following oral dosing, lomeguatrib plasma levels increased after a short lag period, with the time to C_{max} being a median of 2 hours (range, 1-6 hours). Thereafter lomeguatrib levels declined rapidly and were usually undetectable by 12 hours post-dosing. Patients' AUC values on days 1 and 5 were not significantly different from each other (i.v. $P = 0.43$; oral $P = 0.31$, Wilcoxon signed rank test). Across the limited dose range used in this trial, lomeguatrib exhibited linear kinetics with clearance independent of dose, and body surface area had no significant effect on lomeguatrib clearance ($r < 0.3$). Paired pharmacokinetic profiles from 20 different patients were available to allow estimation of the bioavailability of the oral formulation and this was a mean of 27.6% (SD, 23.8) and 27.9% (SD, 22.0) on days 1 and 5, respectively.

Toxicity of lomeguatrib alone and determination of the MTD of temozolomide in combination with the ADD of lomeguatrib. Lomeguatrib was very well tolerated and produced mainly grade

Table 3. ATase recovery in PBMCs

Lomeguatrib dose (mg/m ²)	No. patients*	Route	Day 8 (mean % ± SE)	Day 11 (mean % ± SE)	Day 15 (mean % ± SE)
10	10	Intravenous	18.8 ± 3.08	51.6 ± 8.36	117 ± 16.8
10	16	Oral	30.3 ± 7.37	85.9 ± 19.3	161 ± 42.
20	6	Intravenous	17.1 ± 8.33	40.0 [†]	59.6 ± 17.6
20	6	Oral	21.1 ± 6.01	35.6 ± 11.1	91.3 ± 26.7
40	3	Intravenous	42.9 ± 7.77	67.0 ± 14.1	165 ± 45.6
40	3	Oral	51.5 ± 20.5	51.4 ± 27.0	82.4 ± 8.69

NOTE: Data expressed as percentage of pretreatment ATase activity.
*Number of patients for whom data were obtained at specified dose and route.
†Sample available from only one patient.

1 or 2 adverse effects (Table 5), the most significant adverse effect being local venous irritation with the i.v. formulation and short-lived (<1 hour) mild nausea (mainly at 40 mg/m²). Based on the chemical structures of lomeguatrib and the diluent *N*-methylpyrrolidone, it was considered likely that the local venous pain was diluent related rather than due to lomeguatrib. No significant toxicity was encountered with oral lomeguatrib alone.

The dose levels for lomeguatrib and temozolomide are shown in Table 1. The spectrum of adverse events was in keeping with those reported for temozolomide alone (27, 28) and the DLT of lomeguatrib with temozolomide was hematologic (Tables 5 and 6).

Hematologic toxicity. Hematologic toxicity is summarized by dose level in Table 6. Myelosuppression was an expected toxicity following temozolomide, and in combination with lomeguatrib the degree of myelosuppression was related to temozolomide dose. Grade 4 neutropenia was not encountered at or below dose level 4 but occurred in one of seven patients at level 5 and in two of two patients at level 6. The median day of neutropenia was day 24 (range, days 2-38) and median recovery was by day 30 (range, days 5-50). Grade 3 or 4 thrombocytopenia was observed at doses of temozolomide ≥ 100 mg/m²/d. The median nadir was day 22 (range, days 15-31) and mean recovery was by day 29 (range, days 25-54). Mild anemia was common although grade 3/4 anemia was seen in only three patients. Febrile neutropenia or infection with grade 3 or 4 neutropenia occurred in four patients. The two patients

treated with lomeguatrib 10 mg/m²/d and temozolomide 175 mg/m²/d developed febrile neutropenia and single cases of febrile neutropenia were also seen at dose levels 7 and 8.

Nonhematologic toxicity. No antiemetic prophylaxis was employed during lomeguatrib treatment alone. Nausea and vomiting are well-recognized adverse effects of oral temozolomide, and to ensure therapy compliance, all patients received prophylactic antiemetic therapy with ondansetron (8 mg twice a day orally for 5 days) during combined lomeguatrib and temozolomide. Nausea and vomiting was usually grade 1 or 2 although three patients experienced grade 3 vomiting. Mild fatigue was common and was seen in 16 patients, with three experiencing grade 3 or 4 fatigue. Six patients had venous irritation or pain due to i.v. lomeguatrib administration. This consisted of a burning sensation in the arm during drug administration. Slowing the infusion or the concurrent administration of 0.9% saline abolished the pain.

DLT. Both patients treated at a dose level of 10 mg/m² i.v. lomeguatrib and 175 mg/m² temozolomide experienced DLT (grade 4 thrombocytopenia and grade 4 neutropenia for >5 days). No further dose escalations of temozolomide were made. Dose levels 7 and 8 used 125 mg/m²/d temozolomide with 20 and 40 mg/m² of lomeguatrib (effectively 40 and 80 mg/d with the oral formulation). No significantly increased toxicity was encountered with these increased lomeguatrib doses compared with that seen at 10 mg/m² lomeguatrib with 125 mg/m² temozolomide. A temozolomide dose level of 125

Table 4. Pharmacokinetics of lomeguatrib

	Vc (L)		CL (L/min)		T _{1/2α} (h)		T _{1/2β} (h)	
	Day 1	Day 5	Day 1	Day 5	Day 1	Day 5	Day 1	Day 5
10 mg/m ² i.v. (n = 24)								
Mean	73.0	62.7	85.2	79.7	0.43	0.43	2.79	3.40
SD	42.3	34.5	36.9	46.8	0.17	0.14	1.47	3.12
20 mg/m ² i.v. (n = 3)								
Mean	90.9	59.5	91.6	64.9	0.54	0.40	2.89	2.90
SD	12.8	12.9	10.1	15.2	0.15	0.26	1.48	1.61
40 mg/m ² i.v. (n = 3)								
Mean	99.6	117.7	131.8	102.8	0.47	0.56	3.96	2.64
SD	54.2	52.1	48.1	54.9	0.07	0.04	3.16	2.06
AUC_{0-6 h} following i.v. lomeguatrib								
	10 mg/m ² (n = 24)		20 mg/m ² (n = 3)		40 mg/m ² (n = 3)			
	Day 1	Day 5	Day 1	Day 5	Day 1	Day 5		
Mean	259.9	278.4	440.5	521.6	499.2	837.2		
SD	136.4	196.5	33.6	30.4	141.3	637.6		
AUC_{0-6 h} following oral lomeguatrib								
	10 mg/m ² (n = 12)		20 mg/m ² (n = 3)		40 mg/m ² (n = 3)			
	Day 1	Day 5	Day 1	Day 5	Day 1	Day 5		
Mean	52.7	70.6	115.7	171.0	170.0	219.9		
SD	75.0	64.3	67.4	83.0	65.1	26.3		

Abbreviations: Vc, central volume; CL, clearance; T_{1/2 α} , initial half life; T_{1/2 β} , terminal half life.

Table 5. Nonhematologic adverse events related to lomeguatrib +/- temozolomide

Drug-related adverse event*	No. patients (%)	Maximum grade (90%)			
		1	2	3	4
Laboratory adverse events:					
lomeguatrib alone (<i>n</i> = 38)					
Hypocalcemia	4 (11)	3 (8)	1 (3)	0 (0)	0 (0)
Hyperglycemia	3 (8)	2 (5)	1 (3)	0 (0)	0 (0)
Hyponatremia	3 (8)	3 (8)	0 (0)	0 (0)	0 (0)
Non-laboratory adverse events:					
lomeguatrib alone (<i>n</i> = 38)					
Nausea	6 (16)	5 (13)	1 (3)	0 (0)	N/A
Injection site reaction/pain	5 (13)	3 (8)	2 (5)	0 (0)	0 (0)
Vomiting	3 (8)	3 (8)	0 (0)	0 (0)	0 (0)
Proteinuria	3 (8)	2 (5)	1 (3)	0 (0)	N/A
Laboratory adverse events:					
lomeguatrib and temozolomide (<i>n</i> = 34)					
Hyperglycemia	5 (15)	4 (12)	1 (3)	0 (0)	0 (0)
Hypocalcemia	4 (12)	3 (9)	1 (3)	0 (0)	0 (0)
Lymphopenia	4 (12)	1 (3)	3 (9)	0 (0)	N/A
Alanine aminotransferase	4 (12)	4 (12)	0 (0)	0 (0)	0 (0)
Hypoalbuminemia	3 (9)	2 (6)	1 (3)	0 (0)	N/A
Non-laboratory adverse events:					
lomeguatrib and temozolomide (<i>n</i> = 34)					
Fatigue	16 (47)	9 (26)	4 (12)	2 (6)	1 (3)
Nausea	13 (38)	8 (24)	4 (12)	1 (3)	N/A
Vomiting	8 (24)	5 (15)	0 (0)	3 (9)	0 (0)
Stomatitis/pharyngitis	5 (15)	5 (15)	0 (0)	0 (0)	0 (0)
Proteinuria	3 (9)	3 (9)	0 (0)	0 (0)	0 (0)

NOTE: N/A, not applicable.
*Adverse events occurring in ≥ 3 patients.

mg/m² days 1 to 5 was considered the recommended starting dose for use with an ADD of lomeguatrib (10 mg/m² i.v. or 20-40 mg/m² orally days 1-5). A total of 50 cycles were administered to 16 patients at these dose levels and the maximum grade of toxicity experienced during any cycle with these dose levels was grade 4 thrombocytopenia in 1 of 16 patients, grade 4 neutropenia in 6 patients, and neutropenic fever in 3 patients. There seems to be no advantage to surface area-calculated dosing for lomeguatrib and a regimen of 40 or 80 mg/d orally for 5 days would be suitable for investigation in phase II trials.

Antitumor effects. Twenty-three patients were evaluable for response. At dose level 7, one patient with colorectal cancer, who had received three prior chemotherapy regimens, had a complete response in multiple lung metastases but developed brain metastases after 5 months of treatment. Two patients (one ovarian, one colorectal) had declines of ~50% in serum tumor markers during therapy with stable radiology over five and six cycles, respectively. A further 10 patients had stable disease of at least 3-month duration.

Discussion

The main objectives of this first phase I trial were to determine a dose of lomeguatrib that depleted ATase in patients and to

define a suitable combination of lomeguatrib and temozolomide to be used in future studies. The use of a pharmacodynamic rather than toxicity end point to determine the dose of lomeguatrib for further evaluation was based on the premise that ATase depletion in clinical settings was likely to be achievable at doses well below the MTD of lomeguatrib itself. With the inherent low toxicity of lomeguatrib in preclinical toxicology studies, a starting dose of one third of the ATase inhibitory dose in rodents was chosen as the starting dose for lomeguatrib.

Both PBMC and paired tumor samples were used to determine the extent and the reliability of ATase depletion following administration of lomeguatrib. At the first dose level of 10 mg/m²/d i.v., lomeguatrib was an effective ATase-inactivating agent in human PBMC. It should be noted that lomeguatrib dosing occurred over 5 consecutive days and that additional ATase depletion was expected to occur beyond this early time point. An early time point for the definition of ATase depletion is justified because suppression of ATase activity throughout the duration of temozolomide dosing was deemed important in maximizing the potential for overcoming ATase-mediated resistance.

Lomeguatrib 10 mg/m²/d i.v. produced rapid, complete, and sustained depletion of ATase in PBMC and it is possible that lower doses may also result in complete ATase inactivation in PBMC, but lower doses were not studied. When lomeguatrib was

given orally at 10 mg/m², it took up to 6 hours to achieve maximal depletion and the slower onset of ATase depletion and the relatively low bioavailability probably accounted for the finding that only 10 of 18 patients had total ATase depletion in PBMC at 4 hours. However, at 40 and 80 mg/d orally, all patients had total ATase depletion by 4 hours after the first dose. Recovery of ATase in PBMC was evident within 3 days of completing dosing and ~50% recovery had occurred by 10 days following dosing. In contrast, ATase depletion with temozolomide alone is slow, usually incomplete (even after multiple doses), and ATase levels can recover during continued drug dosing (29, 30).

There is known to be substantial variation in ATase levels in different tumors even with the same histologic type (2) and pretreatment assessment of ATase activity was done to ensure that absent ATase activity reflected drug-induced depletion. In one patient, the pretreatment biopsy revealed undetectable ATase levels, and in two instances, tumor biopsies yielded necrotic material, suggesting that this paired biopsy approach was warranted. Based on tumor depletion data, the tumor ADD identified in this study was 10 mg/m² lomeguatrib i.v. days 1 to 5 (50 mg/m² total dose). This compares to a dose of 120 mg/m² i.v. for O⁶-benzylguanine (31). The tumor ATase depletion data reported here are being extended in ongoing

studies. With oral dosing, low toxicity, and a lack of effect of bovine serum albumin on lomeguatrib pharmacokinetics, a fixed dose rather than body surface area-adjusted dosing can be recommended for future trials.

When administered with an ADD of lomeguatrib, the MTD for temozolomide was 150 mg/m²/d using a day 1 to 5 schedule. To permit ease of administration, an oral regimen is likely to be preferable and a regimen of oral lomeguatrib 40 mg/d with temozolomide 125 mg/m² days 1 to 5 is suggested for further evaluation. Although no DLT was observed in cycle one at this dose level, grade 3 and 4 hematologic toxicity was seen in later cycles in four of six patients, suggesting that an increase in the temozolomide dose to the MTD seen with lomeguatrib 10 mg/m² i.v. would not be sustainable.

A randomized trial of lomeguatrib plus temozolomide versus temozolomide alone in patients with metastatic malignant melanoma is in progress and trials in other tumor types are planned. Work to define the ability of lomeguatrib to deplete ATase in a number of solid tumors is also under way. Because temozolomide has activity in central nervous system tumors, results from this group of patients will be of particular interest.

O⁶-Benzylguanine, the only other ATase inactivator in clinical evaluation, has primarily been used in combination

Table 6. Hematologic toxicity of lomeguatrib and temozolomide (worst grade per patient)

Adverse event	Dose level number*	Dose level Lo/TMZ (mg/m ² /d)	Grade 1	Grade 2	Grade 3	Grade 4
Neutrophils	1	10/50	0	0	0	0
	2	10/75	1	0	0	0
	3	10/100	0	1	0	0
	4	10/125	1	0	1	0
	5	10/150	1	2	2	1
	6	10/175	0	0	0	2
	7	20/125	0	0	0	4
	8	40/125	0	0	1	1
	Total		2	3	3	8
Platelets	1	10/50	1	0	0	0
	2	10/75	1	0	0	0
	3	10/100	0	1	1	0
	4	10/125	0	0	2	0
	5	10/150	2	1	4	0
	6	10/175	0	0	1	1
	7	20/125	1	1	3	1
	8	40/125	0	0	2	0
	Total		5	3	13	2
Hemoglobin	1	10/50	1	0	0	0
	2	10/75	0	1	0	0
	3	10/100	0	0	0	0
	4	10/125	2	1	0	0
	5	10/150	1	2	1	1
	6	10/175	1	1	0	0
	7	20/125	0	3	0	1
	8	40/125	0	2	0	0
	Total		5	10	1	2

Abbreviation: Lo/TMZ, lomeguatrib/temozolomide.

*For dose levels, see Table 1.

with BCNU. With ATase-inactivating doses of O^6 -benzylguanine, only 20% to 25% of the standard dose of BCNU was possible (22). In this study, at tumor ADDs of lomeguatrib, >60% of the standard single agent dose of temozolomide could safely be administered over multiple cycles. A similar observation was made in preclinical studies (16), suggesting that the context of ATase depletion and the choice of O^6 -alkylating agent may be influential. One variable that has not been extensively studied to date has been the optimal duration of ATase inhibition during and following O^6 -alkylator therapy. This may be important as relatively small amounts of newly synthesized ATase may remove DNA adducts. Ultimately, the clinical utility of depleting ATase in tumors to enhance the

therapeutic efficacy of O^6 -alkylating agents will need to be evaluated in randomized phase III trials.

In conclusion, the preclinical development program was highly successful in predicting suitable doses of lomeguatrib for clinical evaluation. Detailed pharmacodynamic assessment of both PBCs and tumors successfully established ADDs of lomeguatrib. Comparative pharmacokinetics using both i.v. and oral formulations of lomeguatrib identified that whereas bioavailability was low, the intrinsic potency and low toxicity of lomeguatrib permit the further clinical evaluation of an oral formulation. This phase I trial successfully identified a suitable dose of temozolomide for use in combination with lomeguatrib for future studies.

References

- Middleton MR, Margison GP. Improvement of chemotherapy efficiency by inactivation of a DNA-repair pathway. *Lancet Oncol* 2003;4:37–44.
- Gerson SL. Clinical relevance of MGMT in the treatment of cancer. *J Clin Oncol* 2002;20:2388–99.
- McElhinney RS, McMurry TB, Margison GP. O^6 -Alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy. *Mini Rev Med Chem* 2003;3:471–85.
- Pegg AE. Properties of mammalian O^6 -alkylguanine-DNA transferases. *Mutat Res* 1990;233:165–75.
- Margison GP, O'Connor PJ. Biological consequences of reactions with DNA: role of specific lesions. In: Cooper CS, Grover PL, editors. *Handbook of experimental pharmacology*. Berlin: Springer-Verlag; 1990. p. 547–71.
- Chen J, Zhang Y, Wang C, et al. O^6 -Methylguanine-DNA methyltransferase activity in human tumors. *Carcinogenesis* 1992;13:1503–7.
- Citron M, Decker R, Chen J, et al. O^6 -Methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung and ovary. *Cancer Res* 1991;51:4131–4.
- Lee SM, Thatcher N, Margison GP. O^6 -Alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. *Cancer Res* 1991;51:619–23.
- Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O^6 -benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. *Cancer Chemother Pharmacol* 1997;40:266–72.
- Micetich K, Futscher B, Koch D, et al. Phase I study of streptozotocin and carmustine sequenced administration in patients with advanced cancer. *J Natl Cancer Inst* 1992;84:256–60.
- Lee SM, Margison GP, Woodcock AA, et al. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. *Br J Cancer* 1993;67:1356–60.
- Smith D, Gerson S, Liu L, et al. Carmustine and streptozotocin in refractory melanoma: an attempt at modulation of O^6 -alkylguanine-DNA alkyltransferase. *Clin Cancer Res* 1996;2:1129–34.
- Clemons M, Ranson M, Margison JM, et al. Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethyl nitrosourea combination therapy in patients with advanced breast cancer. *Int J Cancer* 2003;103:686–92.
- Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O^6 -alkylguanine-DNA alkyltransferase activity by O^6 -benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. *Proc Natl Acad Sci U S A* 1990;87:5368–72.
- Friedman HS, Keir S, Pegg AE, et al. O^6 -Benzylguanine-mediated enhancement of chemotherapy. *Mol Cancer Ther* 2002;1:943–8.
- Middleton MR, Thatcher N, McMurry TB, et al. Effect of O^6 -(4-bromothienyl)guanine on different temozolomide schedules in a human melanoma xenograft model. *Int J Cancer* 2002;100:615–7.
- Kokkinakis DM, Ahmed MM, Chendil D, et al. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O^6 -methylguanine-DNA methyltransferase with O^6 -benzyl-2'-deoxyguanosine. *Clin Cancer Res* 2003;9:1–7.
- Dolan M, Pegg AE. O^6 -Benzylguanine and its role in chemotherapy. *Clin Cancer Res* 1997;3:837–47.
- Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O^6 -benzylguanine for patients with recurrent or progressive malignant glioma. *J Clin Oncol* 2000;18:3522–8.
- Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical and pharmacological study of O^6 -benzylguanine followed by carmustine in patients with advanced cancer. *Clin Cancer Res* 2000;6:3025–31.
- Dolan ME, Posner M, Karrison T, et al. Determination of the optimal modulatory dose of O^6 -benzylguanine in patients with surgically resectable tumors. *Clin Cancer Res* 2002;8:19–23.
- Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O^6 -benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. *J Clin Oncol* 2002;20:2277–83.
- Middleton MR, Kelly J, Thatcher N, et al. O^6 -(4-Bromothienyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. *Int J Cancer* 2000;85:248–52.
- NCI. Guidelines for reporting of adverse drug reactions. Bethesda (MD): National Cancer Institute; 1998.
- World Health Organization. The WHO handbook for reporting results of cancer treatment. WHO publication number 48. Geneva: WHO; 1979.
- Watson AJ, Margison GP. O^6 -Alkylguanine-DNA alkyltransferase assay. *Methods Mol Biol* 2000;152:49–61.
- Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon α -2b or thalidomide in metastatic malignant melanoma. *J Clin Oncol* 2003;21:2551–7.
- van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the EORTC Brain Tumor Group Study 26971. *J Clin Oncol* 2003;21:2525–8.
- Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP. O^6 -Methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II trial. *Int J Cancer* 2000;88:469–73.
- Spiro TP, Liu L, Majka S, Haaga J, Willson JKV, Gerson SL. The effect of once- and twice-a-day dosing on tumor levels of the DNA repair protein O^6 -alkylguanine-DNA-alkyltransferase. *Clin Cancer Res* 2001;7:2309–17.
- Spiro TP, Gerson SL, Liu L, et al. O^6 -Benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. *Cancer Res* 1999;59:2402–10.